Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent antiprotozoal drug |
| gptkbp:approvedBy |
gptkb:FDA
2002 |
| gptkbp:ATCCode |
L01XX26
|
| gptkbp:CASNumber |
58066-85-6
|
| gptkbp:category |
gptkb:alkylphosphocholine
antineoplastic agent |
| gptkbp:chemicalFormula |
C21H46NO4P
|
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:discoveredBy |
gptkb:Asta_Medica
|
| https://www.w3.org/2000/01/rdf-schema#label |
Miltefos
|
| gptkbp:KEGGID |
D02173
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
induces apoptosis
disrupts cell membrane |
| gptkbp:molecularWeight |
407.6 g/mol
|
| gptkbp:origin |
gptkb:Germany
|
| gptkbp:otherName |
gptkb:hexadecylphosphocholine
gptkb:miltefosine |
| gptkbp:PubChem_CID |
gptkb:DB09031
3599 CHEMBL1200982 |
| gptkbp:routeOfAdministration |
oral
topical |
| gptkbp:sideEffect |
vomiting
diarrhea gastrointestinal disturbance teratogenicity |
| gptkbp:UNII |
1M03QO1Z69
|
| gptkbp:usedFor |
gptkb:cancer
gptkb:visceral_leishmaniasis leishmaniasis |
| gptkbp:bfsParent |
gptkb:miltefosine
|
| gptkbp:bfsLayer |
6
|